Literature DB >> 9170450

Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors.

W Weber1, P Bartenstein, M W Gross, D Kinzel, H Daschner, H J Feldmann, G Reidel, S I Ziegler, C Lumenta, M Molls, M Schwaiger.   

Abstract

UNLABELLED: The high glucose utilization of normal gray matter limits the detection of brain tumor tissue by PET using 18F-fluorodeoxyglucose (FDG). The aim of this study was to evaluate whether the examination of amino acid transport with the SPECT tracer 123l-alpha-methyl-L-tyrosine (IMT) allows better identification of tumor tissue than FDG-PET.
METHODS: Nineteen patients (16 with gliomas, 3 with nontumorous lesions) were included in the study. Two independent observers classified PET and SPECT images as positive or negative for tumor tissue and defined the extent of tumor with regions of interest. Tracer uptake of FDG and IMT was quantified by calculating the tumor uptake relative to contralateral gray and white matter.
RESULTS: SPECT studies were interpreted concordantly in 18 patients (kappa = 0.77) and all tumors were identified by both observers. PET studies were interpreted discordantly in 4 patients (kappa = 0.52) and only 10 tumors were identified by both observers, interobserver variability in definition of tumor extent was significantly lower in the IMT-SPECT than in the FDG-PET studies (p = 0.03). Mean tumor uptake relative to gray and white matter was 1.93 +/- 0.42 and 2.25 +/- 0.46 for IMT and 0.93 +/- 0.32 and 1.61 +/- 0.52 for FDG. All tumor uptake ratios were significantly (p < 0.01) higher for IMT than FDG, even when only glioblastomas were analyzed. No significant correlation was observed between the various uptake ratios of FDG and IMT.
CONCLUSION: Despite the lower resolution and lower sensitivity of SPECT compared with PET, IMT-SPECT was clearly superior to FDG-PET in the detection and delineation of tumor tissue.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9170450

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  17 in total

Review 1.  Molecular imaging of gliomas with PET: opportunities and limitations.

Authors:  Christian la Fougère; Bogdana Suchorska; Peter Bartenstein; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2011-07-13       Impact factor: 12.300

2.  [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors.

Authors:  Seung Jin Choi; Jae Seung Kim; Jeong Hoon Kim; Seung Jun Oh; Jeong Gyo Lee; Chang Jin Kim; Young Shin Ra; Jeong Seok Yeo; Jin Sook Ryu; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-02-15       Impact factor: 9.236

3.  Prospective study of p-[123I]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma.

Authors:  Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Andrea Schaefer; Georgios Farmakis; Aleksandar Grgic; Jean R Moringlane; Wolf-Ingo Steudel; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-30       Impact factor: 9.236

4.  3'-Deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging.

Authors:  Yuka Yamamoto; Terence Z Wong; Timothy G Turkington; Thomas C Hawk; David A Reardon; R Edward Coleman
Journal:  Mol Imaging Biol       Date:  2006 Nov-Dec       Impact factor: 3.488

5.  Validation of brain tumour imaging with p-[123I]iodo-L-phenylalanine and SPECT.

Authors:  Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Nadja Sell; Andrea Schaefer; Jean R Moringlane; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-18       Impact factor: 9.236

Review 6.  11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas.

Authors:  Tarun Singhal; Tanjore K Narayanan; Viney Jain; Jogeshwar Mukherjee; Joseph Mantil
Journal:  Mol Imaging Biol       Date:  2007-10-24       Impact factor: 3.488

7.  Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury.

Authors:  Patrick A Hein; Clifford J Eskey; Jeffrey F Dunn; Eugen B Hug
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

8.  Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach.

Authors:  Branislav Jeremic; Biljana Milicic; Danica Grujicic; Aleksandar Dagovic; Jasna Aleksandrovic
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-15       Impact factor: 4.553

9.  11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET.

Authors:  Y Yamamoto; Y Nishiyama; N Kimura; R Kameyama; N Kawai; T Hatakeyama; M Kaji; M Ohkawa
Journal:  Mol Imaging Biol       Date:  2008-06-10       Impact factor: 3.488

Review 10.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.